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Increased erythrocyte 3-DG and AGEs in diabetic hemodialy- Glucose reacts nonenzymatically with protein amino
sis patients: Role of the polyol pathway. groups to initiate glycation, the early stage of the Mail-
Background. 3-Deoxyglucosone (3-DG) accumulating in lard reaction. This process begins with the conversion
uremic serum plays an important role in the formation of ad-
of reversible Schiff base adducts to stable, covalentlyvanced glycation end products (AGEs). To determine if 3-DG
bound Amadori rearrangement products. The levels ofis involved in the formation of intracellular AGEs, we mea-
the Amadori products on numerous proteins are ele-sured the erythrocyte levels of 3-DG and AGEs such as imida-
zolone and Ne-carboxymethyllysine (CML) in hemodialysis vated in proportion to the degree of hyperglycemia in
(HD) patients with diabetes. Further, to determine if the polyol diabetes mellitus. In the intermediate stage of the Mail-
pathway is involved in the formation of erythrocyte 3-DG and lard reaction, the Amadori products can then undergo
AGEs, an aldose reductase inhibitor (ARI) was administered
multiple dehydration and rearrangements to produceto these patients.
highly reactive dicarbonyl compounds such as 3-deox-Methods. The erythrocyte levels of sorbitol, 3-DG, imidazo-
yglucosone (3-deoxy-D-erythro-hexos-2-ulose; 3-DG)lone, and CML were measured in ten diabetic HD patients
before and after treatment with ARI (epalrestat) for eight [1, 2]. 3-DG reacts again with free amino groups, and
weeks, and were compared with those in eleven healthy sub- leads to the formation of advanced glycation end prod-
jects. 3-DG was incubated in vitro with hemoglobin for two ucts (AGEs) in the late stage of the Maillard reaction
weeks to determine if imidazolone and CML are formed by (Fig. 1). 3-DG is demonstrated by reacting with proteinsreacting 3-DG with hemoglobin.
to form AGEs such as imidazolone [3, 4], Ne-carboxy-Results. The erythrocyte levels of sorbitol, 3-DG, imidazo-
methyllysine (CML) [5, 6], pyrraline [7], and pentosi-lone, and CML were significantly elevated in diabetic HD pa-
dine [8].tients as compared with healthy subjects. The erythrocyte levels
of 3-DG significantly decreased after HD, but sorbitol, imidazo- Serum 3-DG levels are elevated in not only diabetic
lone or CML did not. The administration of ARI significantly patients [9], but also uremic patients such as those on
decreased the erythrocyte levels of sorbitol, 3-DG and imidazo- hemodialysis (HD) and continuous ambulatory perito-
lone, and tended to decrease the CML level. Imidazolone was
neal dialysis (CAPD), and undialyzed uremic patientsrapidly produced in vitro by incubating 3-DG with hemoglobin,
[6, 10]. Even as compared to diabetic patients, the serumand CML was also produced, but less markedly as compared
levels of 3-DG are increased in the uremic patients. Thewith imidazolone.
Conclusion. The erythrocyte levels of 3-DG and AGEs are serum levels of 3-DG decrease after HD with a mean
elevated in diabetic HD patients. The administration of ARI reduction rate of 67%, because 3-DG is a small molecule
reduces the erythrocyte levels of 3-DG and AGEs, especially with the molecular weight of 162. After HD, however,
imidazolone, as well as sorbitol. Thus, 3-DG and AGEs, espe- the serum levels of 3-DG were significantly higher thancially imidazolone, in the erythrocytes are produced mainly
those in normal subjects.via the polyol pathway. ARI may prevent diabetic and uremic
On the other hand, polyol pathway may be associatedcomplications associated with AGEs.
with production of 3-DG. Fructose, an oxidized product
of sorbitol by sorbitol dehydrogenase, is converted into
3-DG in vitro [11]. 3-DG has also been reported to beKey words: advanced glycation end products, diabetes mellitus, eryth-
rocytes, aldose reductase inhibitor, hyperglycemia. a biophysical hydrolysis product of fructose 3-phosphate
(F-3-P), which was identified in the lens of diabetic ratsReceived for publication August 26, 1998
[12]. F-3-P is considered to be enzymatically producedand in revised form December 8, 1998
Accepted for publication December 15, 1998 from fructose [13, 14]. These data suggest that the forma-
tion of 3-DG may occur via the polyol pathway. 1999 by the International Society of Nephrology
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Fig. 1. Metabolism of 3-DG. 3-DG, which is synthesized via both the Maillard reaction and the polyol pathway, is involved in the formation of
AGEs such as imidazolone. Aldose reductase inhibitor (ARI) reduces the formation of the AGEs by decreasing the synthesis of 3-DG via the
polyol pathway.
Recently, imidazolones A and B have been isolated with diabetes mellitus. Second, to determine the contri-
bution of polyol pathway to 3-DG production in erythro-as novel AGEs from the incubation solution of 3-DG
and an arginine derivative (Fig. 2) [15, 16]. The formation cytes, we administered an aldose reductase inhibitor
(ARI) to the diabetic HD patients.of imidazolone A by incubating 3-DG with arginine is
very rapid, reaching a maximal concentration within 24
hours, but the formation of imidazolone B is very slow
METHODSand low in quantity even after two weeks [17]. We have
Patientsproduced a monoclonal anti-imidazolone antibody [18,
19]. Immunohistochemistry using this antibody demon- Blood samples were obtained from ten HD patients
strated that imidazolone was localized in b2-microglobu- with diabetes mellitus (7 males, 3 females; 58.2 6 15.4
lin amyloid deposits from uremic patients [18] and in years old, mean 6 sd) before and after HD, and eleven
nodular lesions of kidneys and aortic walls from diabetic healthy subjects (6 males, 5 females). The patients had
patients [19]. Further, immunochemistry demonstrated been treated by HD for 3.5 6 1.7 years. HD was per-
that the imidazolone content in the kidneys of diabetic formed for four hours three times a week. ARI (epalre-
rats was higher than in normal rats [17]. We also pro- stat; Ono Pharmaceutical Co., Osaka, Japan) was admin-
duced a monoclonal anti-CML antibody, and demon- istered to the patients at 150 mg/day for 8 weeks, and
strated that CML was localized in b2-microglobulin amy- the blood samples were collected from the patients be-
fore and after ARI treatment. Epalrestat is approvedloid deposits from uremic patients [20, 21].
The aim of this study was to clarify whether or not by the Japanese government only for the treatment of
diabetic complication, and is widely used in Japan tothe polyol pathway is involved in the formation of 3-DG
and AGEs in the erythrocytes. First, we measured eryth- treat diabetic patients. Thus, the ARI could not be ad-
ministered to non-diabetic HD patients. The heparinizedrocyte levels of 3-DG, sorbitol, and AGEs in HD patients
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GC/MS of erythrocyte 3-DG
After evaporation over nitrogen stream, hydroxyl
groups were converted to their trimethylsilyl derivatives
at 608C for 20 minutes with N,O-bis(trimethylsilyl)-
trifluoroacetoamide (20 ml) containing 1% trimethyl-
chlorosilane (Pierce, Rockford, IL, USA). After cooling
to room temperature, the sample (2 ml) was subjected
to GC/MS (GCMS-QP5000; Shimadzu, Kyoto, Japan)
equipped with a capillary column (30 m 3 0.25 mm i.d.,
0.23 mm thick membrane; J&W Scientific, Folsom, CA,
USA). The column temperature was programmed at
108C/min from 1008C to 2508C. For chemical ionization,
isobutane was used as a reactant gas.
Sample preparation for enzyme-linked immunosorbent
assay (ELISA)
Erythrocyte contents of imidazolone and CML were
measured by ELISA using monoclonal anti-imidazolone
(AG-1) and anti-CML (AG-10) antibodies, according to
the method of Niwa et al [19]. Hemolyzed erythrocytes
(100 ml) were mixed with distilled water (300 ml) and
toluene (300 ml). After centrifugation at 1,500 g for 30
minutes, the supernatant lipid layer was removed. The
water layer (100 ml) was reduced with 50 mm NaBH4
(2.8 ml) at 378C for one hour. After cooling with ice,
Fig. 2. Nonenzymatic formation of imidazolone from 3-DG and arginine. ice-cold 20% (wt/vol) trichloroacetic acid (1.2 ml) was
added to the reduced solution, and the mixture was kept
cool with ice for 30 minutes. After centrifugation at 1,500
g for 45 minutes, the supernatant was removed and the
precipitated protein was dissolved at 48C for two daysblood was centrifuged to separate erythrocytes from
by adding 0.1 m NaOH (450 ml). After neutralizing theplasma. After removing plasma and buffy coat, erythro-
solution with 0.5 m boric acid, the neutral solution wascyte fraction was kept at 2208C until sample preparation.
diluted two or four times with PBS, and then the diluted
solutions were assayed for imidazolone and CML usingSample preparation for gas chromatography/
competitive ELISA. The protein concentration of themass spectrometry
solution was measured by the Lowry method. Then, the
3-DG levels in erythrocytes were measured by using imidazolone and CML contents were expressed as arbi-
gas chromatography/mass spectrometry (GC/MS), ac- trary units (AU) per mg protein.
cording to the method of Niwa et al [6, 9, 10]. 13C6-3-
Competitive sandwich ELISA of erythrocyteDG (1.19 nmol), as an internal standard, was added to
imidazolone and CMLhemolyzed erythrocytes (100 ml), and was diluted with
distilled water (900 ml). The mixture was deproteinized Sample solution (25 ml) or standard AGE-HSA (0 to
200 mg/liter) was incubated at room temperature for oneby addition of ethanol (2 ml), and subsequently centri-
hour in AGE-HSA (10 mg/liter)-coated microplate withfuged at 1,000 g for 10 minutes. The supernatant was
PBS containing 0.25% BSA (50 ml), and peroxidase-applied to a Bond Elut SCX cartridge (cation exchange,
conjugated anti-imidazolone antibody or peroxidase-100 mg in 1 ml; Analytichem International, Harbor City,
conjugated anti-CML antibody. After washing four timesCA, USA), and eluted with distilled water (3 ml). The
with PBS, o-phenylenediamine (100 ml) was added tocollected eluate was then applied to a Bond Elut SAX
the microplate. The reaction was stopped by adding 1.6 m
cartridge (anion exchange, 100 mg in 1 ml; Analytichem H2SO4 (100 ml), and absorption at 492 nm was measuredInternational), and eluted with distilled water (3 ml). using 620 nm as the control.
The eluate was collected, and lyophilized. The carbonyl
Fluorescence spectrophotometry ofgroups of the residue were transformed to their methox-
erythrocyte sorbitolime derivatives at 708C for 30 minutes with 1% me-
thoxylamine hydrochloride (Sigma Chemical, St. Louis, Erythrocyte fraction was diluted two times with PBS.
The hemoglobin contents were determined by Hemoglo-MO, USA) in pyridine (200 ml).
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Fig. 3. Time course of the formation of
AGE-hemoglobin by incubating 3-DG at 378C
with human hemoglobin. The experiments
were done in duplicate, and the data are ex-
pressed as means. The amounts of AGEs (imi-
dazolone and CML) increased time-depen-
dently, although the formation of imidazolone
is obviously marked compared with CML.
bin Test Wako kit (Wako Pure Chemical Industries, RESULTS
Osaka, Japan) in hemolyzed erythrocytes (100 ml) di- Figure 3 demonstrates the production of imidazolone
luted with saline (100 ml). The diluted erythrocyte sample and CML during incubation of human hemoglobin with
(200 ml) was stirred with 10% perchloric acid (200 ml). 3-DG. Although the formation of imidazolone was obvi-
The mixture was kept at 48C for 30 minutes, and then ously marked as compared to CML, the amounts of these
centrifuged at 1,000 g for 10 minutes. The pH of the compounds increased time-dependently, demonstrating
supernatant (300 ml) was adjusted between 8.2 to 9.0 that 3-DG rapidly formed AGEs, especially imidazolone.
with 2 m K2CO3. After standing overnight, the sample Table 1 shows the erythrocyte levels of 3-DG and the
other parameters in diabetic HD patients and in healthywas centrifuged at 1,000 g at 48C for 10 minutes. The
subjects. The diabetic HD patients showed significantlysupernatant (75 ml) was diluted with distilled water (50
elevated erythrocyte levels of sorbitol, 3-DG, imidazo-ml), and the sample solution was incubated with 0.25 m
lone, and CML as compared with the normal subjects.glycine buffer, pH 9.5 (100 ml; Wako Pure Chemical
In the diabetic HD patients, erythrocyte 3-DG levels didIndustries), 12 mm NAD (25 ml; Sigma Chemical Co.),
not show any significant correlation with HbA1c, sorbi-in the presence or absence of 22 U/ml sorbitol dehydro-
tol, imidazolone, CML, or the other parameters. Amonggenase (5 ml; Sigma Chemical Co.) at 378C for 40 minutes.
the other combinations, the significant correlations wereThe fluorescence of NADH produced in the solution
found only between sorbitol and HbA1c (r 5 0.83, P ,was detected by a fluorescence spectrophotometer 850
0.01), between CML and HbAlc (r 5 0.67, P , 0.01),(Hitachi, Tokyo, Japan) at excitation 350 nm and emis-
and between CML and imidazolone (r 5 0.76, P , 0.05).sion 440 nm.
The erythrocyte levels of 3-DG decreased after HD
with a mean reduction rate of 60%, because 3-DG is aIn vitro incubation of hemoglobin with 3-DG
small molecule with the molecular weight of 162. Even
Human hemoglobin (15 mg/ml) (Sigma Chemical) was after HD, the erythrocyte levels of 3-DG in HD patients
incubated with 3-DG (1 mm) in distilled water at 378C were significantly higher than those in normal subjects.
for 14 days. The levels of imidazolone and CML in the However, erythrocyte sorbitol, CML, or imidazolone
mixture were measured by ELISA. could not be removed by HD.
Furthermore, we treated the patients with ARI for
Statistics eight weeks to suppress polyol pathway in erythrocytes.
A non-paired t-test was applied to the comparison As shown in Table 1, the erythrocyte levels of sorbitol
between the groups of healthy subjects and diabetic HD and 3-DG were significantly decreased after ARI ther-
patients. The paired t-test was used in the comparisons apy. The erythrocyte levels of imidazolone were signifi-
between before and after HD, and between pre- and post- cantly decreased by the ARI treatment, and the erythro-
ARI in the group of diabetic HD patients. Significance cyte levels of CML tended to be decreased after the ARI
treatment. However, the mean erythrocyte levels of bothwas found in cases where the P value was less than 0.05.
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Table 1. Erythrocyte levels of sorbitol, 3-deoxyglucosone (3-DG), imidazolone, Nε-carboxymethyllysine (CML), and the other biochemical
parameters in diabetic hemodialysis (HD) patients and healthy subjects, and effects of aldose reductase inhibitor (ARI) on their levels
Diabetic HD (N 5 10)
Pre-ARI Post-ARI
Normal (N 5 11) Before HD After HD Before HD After HD
Serum creatinine mg/dl 0.960.1b 9.860.7 3.8 60.3b 9.760.8 3.860.3
HbA1c % 4.860.1b 8.360.9
Erythrocyte
Sorbitol nmol /g Hb 40.864.6b 73.068.5 68.267.6 53.567.4a 39.763.4c
3-DG nmol /g Hb 13.861.6b 92.4623.0 29.864.8a 48.166.0a 20.862.6c
Imidazolone AU/mg protein 1.7960.13b 6.5461.76 5.9361.37 4.6261.02 4.30 60.94c
CML AU/mg protein 4.5560.38b 9.3760.78 9.6560.84 7.6561.12 7.9060.76
Values are expressed as mean 6 se. AU is arbitrary unit.
a P , 0.05, b P , 0.01 vs. pre-ARI (before HD) by non-paired t or paired t-test
c P , 0.05 pre-ARI (after HD) by paired t-test
imidazolone and CML, which were averaged before and with the reduction rate of 60%, erythrocyte sorbitol and
after HD respectively, were also significantly decreased AGEs could not be removed at all. The reduction rate
after ARI treatment. of erythrocyte 3-DG by HD was similar to that of plasma
3-DG as reported by Niwa et al [6, 10]. Fujii et al demon-
strated that 3-DG easily passes through erythrocyteDISCUSSION
membranes from the incubation medium [25]. The pro-
The erythrocyte levels of sorbitol, 3-DG, and AGEs in duction of 3-DG in erythrocytes may be very rapid, be-
diabetic HD patients were markedly elevated in diabetic cause there is a marked difference between erythrocyte
HD patients as compared with healthy subjects. The and plasma 3-DG levels despite the easy transition of
oral administration of ARI to the diabetic HD patients 3-DG across the erythrocyte membranes. However, the
reduced the erythrocyte levels of 3-DG and AGEs, espe- presence of a specific mechanism to transport 3-DG
cially imidazolone, as well as sorbitol. This evidence across the membranes is not yet known. In contrast,
clearly demonstrates that erythrocyte 3-DG and AGEs, sorbitol hardly passes through the erythrocyte mem-
especially imidazolone, are mainly derived through fruc- branes, and consequently can hardly be removed by HD.
tose from sorbitol produced via the polyol pathway. Because erythrocyte imidazolone and CML are cova-
The mean level of erythrocyte 3-DG in healthy sub-
lently bound mainly to hemoglobin, they cannot be re-
jects was 6.2 mmol/liter, which is three times higher than
moved at all by HD.that in normal plasma (1.9 mmol/liter) [9]. In the other
3-DG was considered to be produced mainly via areports, 3-DG levels in the plasma of healthy subjects
degradation of Amadori products in the Maillard reac-were much lower compared to our results [9]: 62 nmol/
tion until another possibility was pointed out by theliter in a study by Knecht et al [22], and 79 nmol/liter in
discovery of fructose-3-phosphate in rat lens [12] and inHamada et al’s [23] study. To resolve this disagreement,
human erythrocytes [26]. Fructose-3-phosphate, a potentLal et al deproteinized the plasma samples by ultrafiltra-
crosslinking intermediate, yields 3-DG non-enzymati-tion or by the addition of ethanol [24], as described by
cally [14]. Fructose is not utilized in vivo except for itsNiwa et al [9], and measured the normal plasma level
metabolism into fructose 6-phosphate in the glycolyticof 3-DG by GC/MS. The normal plasma level of 3-DG
pathway, and that hexokinase scarcely phosphorylatesdeproteinized by ultrafiltration was 58 nmol/liter, whereas
fructose in a glucose-rich condition because of its sub-the levels deproteinized by ethanol was 1.7 mmol/liter,
strate affinity. Recently, Petersen et al reported thatsimilar to our data. Thus, Lal et al demonstrated that
erythrocyte fructose is phosphorylated to fructose 3-phos-this disagreement was due to the difference in the meth-
phate in an incubation solution including glucose at 5 mmods for deproteinization of the samples, and they consid-
[27]. We consider that fructose and its metabolite, fruc-ered that the greatly increased 3-DG observed upon
tose-3-phosphate, derived from the polyol pathway playethanol extraction is likely to be due to an ethanol-
an important role in the formation of erythrocyte 3-DG,mediated release of 3-DG bound to plasma macromole-
especially in diabetic patients.cules, probably proteins. In the present study, we ex-
3-DG is detoxified mainly to 3-deoxyfructose by re-tracted 3-DG using ethanol to obtain total amounts of
ducing enzymes or to 2-keto-3-deoxygluconic acid by3-DG, including free and protein-bound forms in the
oxoaldehyde dehydrogenase [25]. Some reductases wereerythrocytes.
Although erythrocyte 3-DG could be removed by HD identified as aldehyde reductases [28, 29] and aldose
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3. Konishi Y, Hayase F, Kato H: Novel imidazolones compoundreductases [29, 30], which are included in the aldo-keto
formed by the advanced Maillard reaction of 3-deoxyglucosone
reductase superfamily [31] and dihydrodiol dehydroge- and arginine residues in proteins. Biosci Biotech Biochem 58:1953–
nases [32]. 3-Deoxyfructose has been detected in the 1955, 1994
4. Hayase F, Konishi Y, Kato H: Identification of the modifiedhuman urine and plasma [33]. The ability to detoxify
structure of arginine residues in proteins with 3-deoxyglucosone,3-DG by these enzymes may provide a genetic basis for a Maillard reaction intermediate. Biosci Biotech Biochem 59:1407–
the differences in the severity of age-related pathologies 1411, 1995
5. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichiand diabetic complications. The elevated levels of serum
N, Takei Y, Kondo T: Amyloid b2-microglobulin is modified with3-DG in diabetic patients may be due to the increased Ne-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney
production of 3-DG via the Maillard reaction resulting Int 50:1303–1309, 1996
6. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Miyazakifrom hyperglycemia, while the increased levels of eryth-
S, Tatemichi N, Takei Y: Modification of b2-m with advancedrocyte 3-DG is due to the enhanced polyol pathway. glycation end products as observed in dialysis-related amyloidosis
3-DG stimulates the formation of AGEs, which then by 3-DG accumulating in uremic serum. Kidney Int 49:861–867,
1996show a number of biological activities and are involved
7. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM:in the pathogenesis of diseases such as diabetes and aging Aging of proteins: Immunological detection of a glucose-derived
[34]. Recently, however, 3-DG itself also has been dem- pyrrole formed during Maillard reaction in vivo. J Biol Chem
264:3758–3764, 1989onstrated to have some biological activities. 3-DG in-
8. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW: Formationduced heparin-binding epidermal growth factor-like of pentosidine during nonenzymatic browning of proteins by glu-
growth factor in rat aortic smooth muscle cells [35], and cose. J Biol Chem 266:11654–11660, 1991
9. Niwa T, Takeda N, Yoshizumi H, Tatematsu A, Ohara M, Tomi-may be involved in the development of atherosclerosis.
yama S, Niimura K: Presence of 3-deoxyglucosone, a potent protein3-DG induces apoptotic cell death in macrophage- crosslinking intermediate of Maillard reaction, in diabetic serum.
derived cell lines [36], and suppresses cell-cycle progres- Biochem Biophys Res Commun 196:837–843, 1993
10. Niwa T, Takeda N, Miyazaki T, Yoshizumi H, Tatematsu A,sion during the S phase of rat fibroblasts [37]. Thus,
Maeda K, Ohara M, Tomiyama S, Niimura K: Elevated serum3-DG is thought to be a glycotoxin or a uremic toxin,
levels of 3-deoxyglucosone, a potent protein-cross-linking interme-
and may be involved in the pathogenesis of diabetic and/ diate of the Maillard reaction, in uremic patients. Nephron 69:438–
443, 1995or uremic complications.
11. Kato H, Yamamoto M, Fujimaki M: Mechanisms of browningThe polyol pathway is enhanced not only in erythro-
degradation of D-fructose in special comparison with D-glucose-
cytes, but also in other tissues such as peripheral nerves, glycine reaction. Agric Biol Chem 33:939–948, 1969
12. Szwelgold BS, Kappler F, Brown TR: Identification of fructose-lens, retina, aortas, and kidneys in diabetic patients, be-
3-phosphate in the lens of diabetic rats. Science 247:451–454, 1990cause these tissues contain aldose reductase [38]. The
13. Lal S, Benjamin S, Szwergold FK, Brown T: Detection of fruc-
enhanced polyol pathway leads to the intracellular accu- tose-3-phosphokinase activity in intact mammalian lenses by 31P
mulation of sorbitol and fructose in these tissues. As we NMR spectroscopy. J Biol Chem 268:7763–7767, 1993
14. Lal S, Szwergold BS, Taylor AH, Randall WC, Kappler F,observed in erythrocytes, and contents of intracellular
Wells KK, Baynes JW, Brown TR: Metabolism of fructose-3-3-DG and AGEs, especially imidazolone, in these tissues phosphate in the diabetic rat lens. Arch Biochem Biophys 318:191–
may also be increased in diabetic HD patients, because 199, 1995
15. Konishi Y, Hayase F, Kato H: Novel imidazolones compoundthey are produced via the polyol pathway. The adminis-
formed by the advanced Maillard reaction of 3-deoxyglucosonetration of ARI may also decrease the intracellular 3-DG and arginine residues in proteins. Biosci Biotechnol Biochem
and AGEs in these tissues by reducing the sorbitol con- 58:1953–1955, 1994
16. Hayase F, Konishi Y, Kato H: Identification of the modifiedcentration.
structure of arginine residues in proteins with 3-deoxyglucosone,In conclusion, the high levels of 3-DG and AGEs, a Maillard reaction intermediate. Biosci Biotechnol Biochem
especially imidazolone, in the erythrocytes of diabetic 59:1407–1411, 1995
17. Niwa T, Katsuzaki T, Ishizaki Y, Hayase F, Miyazaki T,HD patients are due mainly to the enhanced polyol path-
Uematsu T, Tatemichi N, Takei Y: Imidazolone, a novel advancedway. ARI may prevent the development of diabetic and/
glycation end product, is present at high levels in kidneys of rats
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